Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …

Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …

PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …